ADPT ADAPTIVE BIOTECHNOLOGIES COR revenue, earnings and financials

For the quarter ended June 30, 2026, ADAPTIVE BIOTECHNOLOGIES COR reported revenue of $71.6M (up 21.5% from a year earlier), net income of −$39.8M and diluted EPS of −$0.25; over the last four quarters revenue was $308M and net income −$63.9M; for the fiscal year ended December 2025 revenue was $277M, up 54.8% on the year before.

ADPT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $277M, gross profit n/a, operating income −$57.1M, net income −$59.5M (margin -21.5%), EPS −$0.39
• Fiscal year ended Dec 2024: revenue $179M, gross profit n/a, operating income −$163M, net income −$159M (margin -89.1%), EPS −$1.08
• Fiscal year ended Dec 2023: revenue $170M, gross profit n/a, operating income −$227M, net income −$225M (margin -132.3%), EPS −$1.56
• Fiscal year ended Dec 2022: revenue $185M, gross profit n/a, operating income −$200M, net income −$200M (margin -108.0%), EPS −$1.40
• Fiscal year ended Dec 2021: revenue $154M, gross profit n/a, operating income −$209M, net income −$207M (margin -134.3%), EPS −$1.48

ADPT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $71.6M (up 21.5% year over year), net income −$39.8M, EPS −$0.25
• Quarter ended Mar 31, 2026: revenue $70.9M (up 35.1% year over year), net income −$20.0M, EPS −$0.13
• Quarter ended Dec 31, 2025 (from the annual report): revenue $71.7M (up 51.0% year over year), net income −$13.6M, EPS −$0.08
• Quarter ended Sep 30, 2025: revenue $94.0M (up 102.4% year over year), net income $9.55M, EPS $0.06
• Quarter ended Jun 30, 2025: revenue $58.9M (up 36.3% year over year), net income −$25.6M, EPS −$0.17
• Quarter ended Mar 31, 2025: revenue $52.4M (up 25.2% year over year), net income −$29.9M, EPS −$0.20
• Quarter ended Dec 31, 2024 (from the annual report): revenue $47.5M (up 3.7% year over year), net income −$33.7M, EPS −$0.22
• Quarter ended Sep 30, 2024: revenue $46.4M (up 22.5% year over year), net income −$32.1M, EPS −$0.22
• Quarter ended Jun 30, 2024: revenue $43.2M (down 11.7% year over year), net income −$46.2M, EPS −$0.31
• Quarter ended Mar 31, 2024: revenue $41.9M (up 11.2% year over year), net income −$47.5M, EPS −$0.33
• Quarter ended Dec 31, 2023 (from the annual report): revenue $45.8M (down 17.1% year over year), net income −$69.4M, EPS −$0.48
• Quarter ended Sep 30, 2023: revenue $37.9M (down 20.7% year over year), net income −$50.3M, EPS −$0.35
• Quarter ended Jun 30, 2023: revenue $48.9M (up 12.1% year over year), net income −$47.8M, EPS −$0.33
• Quarter ended Mar 31, 2023: revenue $37.6M (down 2.5% year over year), net income −$57.7M, EPS −$0.40
• Quarter ended Dec 31, 2022 (from the annual report): revenue $55.2M (up 45.5% year over year), net income −$40.1M, EPS −$0.27
• Quarter ended Sep 30, 2022: revenue $47.8M (up 21.2% year over year), net income −$45.3M, EPS −$0.32
• Quarter ended Jun 30, 2022: revenue $43.7M (up 13.4% year over year), net income −$52.0M, EPS −$0.37
• Quarter ended Mar 31, 2022: revenue $38.6M (up 0.5% year over year), net income −$62.7M, EPS −$0.44
• Quarter ended Dec 31, 2021 (from the annual report): revenue $37.9M, net income −$61.4M, EPS −$0.44
• Quarter ended Sep 30, 2021: revenue $39.5M, net income −$55.9M, EPS −$0.40

ADPT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$46.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$95.2M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$156M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$184M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$193M, share buybacks n/a

ADPT balance sheet

• Jun 30, 2026: cash $170M, total assets $641M, total liabilities $490M, shareholders' equity $143M, long-term debt $0
• Mar 31, 2026: cash $77.6M, total assets $506M, total liabilities $282M, shareholders' equity $216M, long-term debt $125M
• Dec 31, 2025: cash $70.5M, total assets $513M, total liabilities $288M, shareholders' equity $219M, long-term debt $127M
• Sep 30, 2025: cash $55.0M, total assets $491M, total liabilities $286M, shareholders' equity $204M, long-term debt $129M
• Jun 30, 2025: cash $43.2M, total assets $497M, total liabilities $317M, shareholders' equity $180M, long-term debt $130M
• Mar 31, 2025: cash $50.6M, total assets $511M, total liabilities $321M, shareholders' equity $190M, long-term debt $132M
• Dec 31, 2024: cash $47.9M, total assets $539M, total liabilities $337M, shareholders' equity $203M, long-term debt $132M
• Sep 30, 2024: cash $38.1M, total assets $559M, total liabilities $335M, shareholders' equity $224M, long-term debt $133M

What is ADPT's revenue?

ADAPTIVE BIOTECHNOLOGIES COR reported $308M of revenue over its last four quarters, through June 30, 2026.

Is ADPT profitable?

No. ADAPTIVE BIOTECHNOLOGIES COR lost $63.9M over the last four quarters.

What is ADPT's EPS?

Diluted earnings per share over the last four quarters were −$0.40; −$0.25 in the latest quarter.

ADPT ownership and insider trades · All stocks